Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake

Bioconjugate Chemistry

Volumn 23, Issue 6, 2012, Pages 1341-1348

  Guo, Haixun ^a   Gallazzi, Fabio ^d   Miao, Yubin ^a,b,c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; DERMATOLOGY; GALLIUM; MAMMALS; PEPTIDES; PHARMACOKINETICS; TUMORS;

BINDING AFFINITIES; C57 MICE; LACTAM BRIDGES; MELANOCORTINS; MELANOMA CELLS; PHARMACOKINETIC PROPERTIES; RADIOLABELLING; RECEPTOR BINDING; TETRAACETIC ACID; TRIAZACYCLONONANE;

ONCOLOGY;

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID GLYCYLCGLYCYLNORLEUCINE C [ASPARTYLHISTIDYL DEXTRO PHENYLARIGNYLTRYTOPHYLLYSINE]AMIDE GA 67; 1,4,7,10 TETRAAZACYCLONONANE 1,4,7,10 TETRAACETIC ACID GLYCYLGLUTAMYL C [LYSYLNORLEUCYLGLUTAMYLHISTIDYL DEXTRO PHENYLARGINYLTRYTOPHYLARGINYLPROLYLVALYLASPARTIC ACID]; 1,4,7,10 TETRAAZACYCLONONANE 1,4,7,10 TETRAACETIC ACID GLYCYLGLYCYLNORLEUCINE C [ASPARTYLHISTIDYL DEXTRO PHENYLARGINYLTRYPTOPHYLLYSINE]AMIDE GA 67; AMIDE; ANTINEOPLASTIC AGENT; CARBONYL DERIVATIVE; FLUORENYLMETHYLOXY CARBONYL; GALLIUM 67; LACTAM DERIVATIVE; MELANOCORTIN 1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; MELANOMA; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; REACTION TIME; RECEPTOR BINDING; SYNTHESIS;

ALPHA-MSH; ANIMALS; CELL LINE, TUMOR; CYCLIZATION; FEMALE; GALLIUM RADIOISOTOPES; KIDNEY; LACTAMS; MELANOMA; MICE; MICE, INBRED C57BL; PEPTIDES, CYCLIC; RECEPTOR, MELANOCORTIN, TYPE 1; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84862705209     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300191z     Document Type: Article

References (33)

1. Giblin, M. F., Wang, N. N., Hoffman, T. J., Jurisson, S. S., and Quinn, T. P. (1998) Design and characterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc. Natl. Acad. Sci. U.S.A. 95, 12814-12818.
2. 99mtechnetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 60, 5649-5658.
3. 111In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J. Nucl. Med. 42, 1847-1855.
4. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int. J. Cancer 101, 480-487.
5. Froidevaux, S., Calame-Christe, M., Tanner, H., Sumanovski, L., and Eberle, A. N. (2002) A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J. Nucl. Med. 43, 1699-1706.
6. 111In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J. Med. Chem. 45, 3048-3056.
7. Miao, Y., Whitener, D., Feng, W., Owen, N. K., Chen, J., and Quinn, T. P. (2003) Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjugate Chem. 14, 1177-1184.
8. Froidevaux, S., Calame-Christe, M., Schuhmacher, J., Tanner, H., Saffrich, R., Henze, M., and Eberle, A. N. (2004) A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J. Nucl. Med. 45, 116-123.
9. 188Re-labeled alpha-melanocyte- stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J. Nucl. Med. 46, 121-129.
10. Froidevaux, S., Calame-Christe, M., Tanner, H., and Eberle, A. N. (2005) Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J. Nucl. Med. 46, 887-895.
11. Miao, Y., Hylarides, M., Fisher, D. R., Shelton, T., Moore, H., Wester, D. W., Fritzberg, A. R., Winkelmann, C. T., Hoffman, T. J., and Quinn, T. P. (2005) Melanoma therapy via peptide-targeted alpha-radiation. Clin. Cancer Res. 11, 5616-5621.
12. 86Y-DOTA- ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J. Med. Chem. 48, 2985-2992.
13. 177Lu-labeled α-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl. Med. Biol. 32, 485-493.
14. 177Lu labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl. Med. Biol. 33, 723-733.
15. 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J. Nucl. Med. 48, 64-72.
16. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for MicroPET imaging of melanocortin 1 receptor expression. Bioconjugate Chem. 18, 765-772.
17. 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J. Nucl. Med. 48, 73-80.
18. 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother. Radiopharm. 22, 333-341.
19. 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjugate Chem. 19, 539-547.
20. 111In-labeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptide. Nucl. Med. Biol. 36, 267-276.
21. 111In-labeled lactam bridge-cyclized α-melanocyte stimulating hormone peptide. Bioconjugate Chem. 20, 2162-2168.
22. Guo, H., Yang, J., Shenoy, N., and Miao, Y. (2009) Gallium-67-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide for primary and metastatic melanoma imaging. Bioconjugate Chem. 20, 2356-2363.
23. Guo, H., Yang, J., Gallazzi, F., and Miao, Y. (2010) Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide resulting in enhanced melanoma uptake. J. Nucl. Med. 51, 418-426.
24. Guo, H., Yang, J., Gallazzi, F., and Miao, Y. (2011) Effects of the amino acid linkers on melanoma-targeting and pharmacokinetic properties of Indium-111-labeled lactam bridge-cyclized α-MSH peptides. J. Nucl. Med. 52, 608-616.
25. +: effect of cyclization on tumor-seeking properties. J. Biol. Inorg. Chem. 13, 449-459.
26. 3-labeled pyrazolyl-α-melanocyte-stimulating hormone analog conjugate for melanoma targeting. Nucl. Med. Biol. 35, 91-99.
27. Mariani, G., Bodei, L., Adelstein, S. J., and Kassis, A. I. (2000) Emerging roles for radiometabolic therapy of tumors based on auger electron emission. J. Nucl. Med. 41, 1519-1521.
28. Clarke, E. T., and Martell, A. E. (1991) Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13-, and 14- membered tetraazamacrocycles. Inorg. Chim. Acta 190, 37-46.
29. Clarke, E. T., and Martell, A. E. (1991) Stabilities of the Fe(III), Ga(III) and In(III) chelators of N,N′,N″;-triazacyclononanetriacetic acid. Inorg. Chim. Acta 181, 273-280.
30. Green, M. A., and Welch, M. J. (1989) Gallium radiopharmaceutical chemistry. Int. J. Rad. Appl. Instrum. B 16, 435-448.
31. Anderson, C. J., and Welch, M. J. (1999) Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem. Rev. 99, 2219-2234.
32. 67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expression tumors. Bioconjugate Chem. 13, 530-541.
33. 67Ga-DOTATOC SPECT. Eur. J. Nucl. Med. Mol. Imaging 32, 1129.